Enhance your podiatry practice with evidence-based diabetic foot screening protocols that integrate autonomic and vascular diagnostics to better stratify amputation risk.
Published October 30, 2026 · Updated November 5, 2026
For the modern podiatrist, the primary objective is moving beyond reactive wound care toward proactive risk stratification. With the global prevalence of diabetes mellitus, the burden of foot complications remains a significant public health challenge. According to the American Diabetes Association (ADA), early identification of peripheral neuropathy and vascular insufficiency is the cornerstone of preventing diabetic foot ulcers. A robust diabetic foot screening protocol must integrate sensory, vascular, and autonomic assessments to provide a complete clinical picture.
Traditional clinical assessments often focus exclusively on the 10-gram monofilament test and palpation of pedal pulses. While these are essential, they are inherently limited in their ability to detect subclinical autonomic dysfunction—a silent driver of distal perfusion issues and skin integrity loss. Relying solely on these manual tests risks missing the early signs of diabetic neuropathy assessment in podiatry, where sudomotor dysfunction often precedes sensory deficits.
To effectively stratify foot ulcer risk, podiatrists should adopt a multi-modal diagnostic approach. The integration of advanced physiological testing allows for a more granular understanding of a patient's risk profile. The VitalScan ANS+ system, developed by US MedResources, offers a non-invasive diagnostic suite that bridges this gap.
Autonomic neuropathy is a major contributor to dry skin, fissures, and Charcot neuroarthropathy. The VitalScan ANS+ provides automated testing for sudomotor function (SudoCheck), heart rate variability (HRV), and Valsalva ratio. By identifying autonomic impairment before gross sensory loss occurs, clinicians can intervene with more aggressive offloading and preventative education. This objective data is billable under CPT codes 95921-95924, ensuring that high-level diagnostics remain revenue-neutral or revenue-positive for the practice.
Peripheral Artery Disease (PAD) is frequently underestimated in the diabetic population due to medial calcinosis, which renders standard ABI readings unreliable. The VitalScan ANS+ includes advanced vascular foot screening capabilities, such as Pulse Wave Velocity (PWV) and specialized Ankle-Brachial Index (ABI) analysis. These assessments, billable under CPT 93922-93971, provide the necessary physiological evidence to document vascular health and guide referrals for revascularization where indicated.
Practice managers often express concern regarding the time commitment required for comprehensive diagnostics. However, the VitalScan ANS+ system is designed for high-efficiency clinical environments. The entire test battery can be administered by existing clinical staff in approximately 15 minutes, with no specialized technician required. The automated, interpretive report is generated immediately, allowing the podiatrist to review the findings with the patient during the same office visit. This real-time feedback loop has been shown to increase patient engagement and adherence to recommended foot care routines.
By incorporating these diagnostic modalities, practices align their standard of care with the latest evidence-based guidelines from the ADA, AHA, and ACC. These organizations emphasize that the diabetic foot exam should not be a static event but a dynamic process that tracks progression over time. Systematic data collection through the VitalScan ANS+ platform allows for longitudinal monitoring of cardiovascular and microvascular metrics, creating a defensible clinical record for high-risk patients.
Comprehensive diabetic foot screening requires moving beyond traditional palpation and monofilament testing. By integrating advanced autonomic and vascular diagnostics—such as HRV, sudomotor testing, and specialized ABI—podiatrists can accurately identify patients at high risk for ulceration before irreversible damage occurs. Utilizing the 15-minute, staff-administered VitalScan ANS+ system streamlines this process, ensuring that evidence-based risk stratification is feasible, billable (CPT 95921-95924, 93922-93971), and highly effective in modern clinical practice.
One-Page Reference
Code descriptions, typical reimbursement ranges, ICD-10 pairings, and the CMS bundling note to check before you bill.
Your diabetic patients already need this. See what adding the tests to your existing visits produces per month.